Literature DB >> 11435450

Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.

C Patrono1, P Patrignani, L A García Rodríguez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11435450      PMCID： PMC209347          DOI： 10.1172/JCI13418

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  30 in total

1.  Is cyclooxygenase-2 the alpha and the omega in cancer?

Authors:  S M Prescott
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 2.  Chemoprevention of colorectal cancer.

Authors:  P A Jänne; R J Mayer
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

3.  Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study.

Authors:  L A García Rodríguez; C Huerta-Alvarez
Journal:  Epidemiology       Date:  2000-07       Impact factor: 4.822

4.  Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators.

Authors:  D W Taylor; H J Barnett; R B Haynes; G G Ferguson; D L Sackett; K E Thorpe; D Simard; F L Silver; V Hachinski; G P Clagett; R Barnes; J D Spence
Journal:  Lancet       Date:  1999-06-26       Impact factor: 79.321

5.  Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.

Authors:  M R Panara; G Renda; M G Sciulli; G Santini; M Di Giamberardino; M T Rotondo; S Tacconelli; F Seta; C Patrono; P Patrignani
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

6.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

7.  Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation.

Authors:  B F McAdam; I A Mardini; A Habib; A Burke; J A Lawson; S Kapoor; G A FitzGerald
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 8.  Cyclooxygenase-2 and carcinogenesis.

Authors:  S M Prescott; F A Fitzpatrick
Journal:  Biochim Biophys Acta       Date:  2000-03-27

9.  Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

Authors:  C C Chan; S Boyce; C Brideau; S Charleson; W Cromlish; D Ethier; J Evans; A W Ford-Hutchinson; M J Forrest; J Y Gauthier; R Gordon; M Gresser; J Guay; S Kargman; B Kennedy; Y Leblanc; S Leger; J Mancini; G P O'Neill; M Ouellet; D Patrick; M D Percival; H Perrier; P Prasit; I Rodger
Journal:  J Pharmacol Exp Ther       Date:  1999-08       Impact factor: 4.030

10.  Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.

Authors:  T D Warner; F Giuliano; I Vojnovic; A Bukasa; J A Mitchell; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205
View more
  58 in total

Review 1.  Genetic and pharmacological analysis of prostanoid receptor function.

Authors:  S Narumiya; G A FitzGerald
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 2.  Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways.

Authors:  C N Serhan; E Oliw
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

3.  Turning down insulin signaling.

Authors:  M J Birnbaum
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

4.  The expanding network of redox signaling: new observations, complexities, and perspectives.

Authors:  Roy J Soberman
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

Review 5.  Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

6.  Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly.

Authors:  Kathrine F Vandraas; Olav Spigset; Milada Mahic; Lars Slørdal
Journal:  Eur J Clin Pharmacol       Date:  2010-04-20       Impact factor: 2.953

Review 7.  Risk of anastomotic leakage with use of NSAIDs after gastrointestinal surgery.

Authors:  Christian Fredrik Rushfeldt; Baldur Sveinbjørnsson; Kjetil Søreide; Barthold Vonen
Journal:  Int J Colorectal Dis       Date:  2011-08-11       Impact factor: 2.571

8.  NSAIDs and cardiovascular disease: time to say no to diclofenac.

Authors:  Patompong Ungprasert
Journal:  Intern Emerg Med       Date:  2015-08-26       Impact factor: 3.397

9.  COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations.

Authors:  Karen W Makar; Elizabeth M Poole; Alexa J Resler; Brenna Seufert; Karen Curtin; Sarah E Kleinstein; David Duggan; Richard J Kulmacz; Li Hsu; John Whitton; Christopher S Carlson; Christine F Rimorin; Bette J Caan; John A Baron; John D Potter; Martha L Slattery; Cornelia M Ulrich
Journal:  Cancer Causes Control       Date:  2013-12       Impact factor: 2.506

10.  Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction.

Authors:  Raymond G Schlienger; Hershel Jick; Christoph R Meier
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.